Table 5.
Factors associated with progression to blast phase in 139 accelerated phase chronic myeloid leukemia patients treated with imatinib.
| Variables | Bivariate analysis |
p-Value | Multivariate analysis |
p-Value | ||
|---|---|---|---|---|---|---|
| OR | 95% CI | OR | 95% CI | |||
| Time between CML Dx and Rx with imatinib > 12 months | 3.27 | 1.21–8.85 | 0.014 | 3.12 | 1.11–8.75 | 0.03 |
| PB basophils ≥ 20% | 8.08 | 1.33–49.18 | 0.007 | 7.77 | 1.32–45.62 | 0.023 |
| Hemoglobin < 10 g/dL | 3.79 | 1.48–9.69 | 0.003 | 3.94 | 1.53–10.15 | 0.005 |
OR: odds ratio; 95% CI: 95% confidence interval; Dx: diagnosis; Rx: treatment; PB: peripheral blood.